
ai3Bio raises $48M to reset immune systems for remission
Boston biotech emerges from stealth with dual platforms targeting disease-causing Th17 cells, aiming to deliver lasting autoimmune remission rather than lifetime symptom management.
We baked up some cookies – the digital kind. They help Draper run like a well-oiled mid-century machine. Some are essential to the experience, others help us tailor things to your taste. We promise, no crumbs on your blazer. Take a moment to choose what works for you.
